Objectives: The aims of the study were to investigate the systematic classification of subsidiary behaviors during visual display terminal (VDT) work and discuss the interpretation of these behaviors through an interactive model of subsidiary behaviors, work performance and autonomic nerve activity.
Methods: Twelve university students were instructed to perform continuous 120-min English transcription tasks in a sedentary posture. Data on subsidiary behaviors, work performance (mean keystroke and mean error rates), and autonomic nervous system balance (log-transformed low frequency (LF) / high frequency (HF) ratio) were recorded every 5 min during VDT work.
Results: The subsidiary behaviors were categorized into 3 qualitatively independent factors: distractive behaviors against monotony (DBM), sleepiness-related behaviors (SRB), and habitual behaviors (HB). A cross-correlation analysis indicated that an increase of DBM, which is considered as a sign of workers' attempt to escape from monotonous task operations, was related to a decline in performance. A decrease in the LF/HF ratio was followed by SRB after 5 min passed (r=-0.57, p<0.05), eventually leading to a restriction of the deterioration in performance. An increase of DBM was predictive of an increase in errors (r=0.54, p<0.05), and a significant negative correlation (r=-0.46, p<0.05) between HB and autonomic nerve activity at 10 min after the appearance of HB was observed.
Conclusion: It emerged from the results that the factor structure of subsidiary behaviors consists of 3 mutually independent factors. The interactive model suggests that subsidiary behaviors are possibly precursory signs of errors and changes in autonomic nervous system balance.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1539/joh.l9110 | DOI Listing |
Neurobiol Aging
December 2024
Center for Lifespan Changes in Brain and Cognition, Department of Psychology, University of Oslo, Oslo 0373, Norway.
Structural brain changes underlie cognitive changes and interindividual variability in cognition in older age. By using structural MRI data-driven clustering, we aimed to identify subgroups of cognitively unimpaired older adults based on brain change patterns and assess how changes in cortical thickness, surface area, and subcortical volume relate to cognitive change. We tested (1) which brain structural changes predict cognitive change (2) whether these are associated with core cerebrospinal fluid (CSF) Alzheimer's disease biomarkers, and (3) the degree of overlap between clusters derived from different structural modalities in 1899 cognitively healthy older adults followed up to 16 years.
View Article and Find Full Text PDFBMC Gastroenterol
December 2024
Department of Inflammatory Bowel Disease, St Mark's National Bowel Hospital, Central Middlesex Hospital, Acton Lane, London, NW10 7NS, UK.
Background: With 20-40% of patients who have inflammatory bowel disease (IBD) not responding to therapy, resource use and costs can be high. We performed a descriptive analysis of health-care data for IBD management in the National Health Service to explore potential areas for improvement.
Methods: In this exploratory study, we analysed real-world data from the Discover dataset for adults with a diagnosis of incident IBD recorded in northwest London, UK, between 31 March, 2016, and 31 March, 2020.
Background: Few treatments are available for individuals with marked treatment-resistant depression (TRD).
Objective: Evaluate the safety and effectiveness of FDA-approved adjunctive vagus nerve stimulation (VNS) in patients with marked TRD.
Methods: This 12-month, multicenter, double-blind, sham-controlled trial included 493 adults with marked treatment-resistant major depression who were randomized to active or no-stimulation sham VNS for 12 months.
J Affect Disord
December 2024
Compass Pathfinder Ltd (a subsidiary of Compass Pathways plc), London, UK.
Objective: To determine the relationships between psilocybin dose, psychedelic experiences, and therapeutic outcome in treatment-resistant depression.
Methods: For treatment-resistant depression, 233 participants received a single dose of 25, 10, or 1 mg of COMP360 psilocybin (a proprietary, pharmaceutical-grade synthesized psilocybin formulation, developed by the sponsor, Compass Pathfinder Ltd.) with psychological support.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!